Montelukast

Leukotriene Receptor Antagonist — Respiratory

• Drug Class: Leukotriene Receptor Antagonist
• Category: Respiratory
• Type: Small Molecule
• SMILES: CC(C)(O)c1ccccc1CC/C(SCC1(CC(=O)O)CC1)=C\c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1

What is Montelukast?

Montelukast is a widely prescribed medication belonging to the class of drugs known as leukotriene receptor antagonists (LTRAs). It is primarily used to manage chronic asthma and to relieve symptoms of seasonal and perennial allergic rhinitis. Available as a generic medication and under brand names such as Singulair, montelukast offers a targeted approach to managing inflammatory pathways involved in respiratory conditions. Its efficacy in reducing airway inflammation and bronchoconstriction has made it a cornerstone therapy for many patients seeking relief from breathing difficulties.

Mechanism of Action

Montelukast exerts its therapeutic effects by selectively and potently inhibiting the action of cysteinyl leukotriene 1 (CysLT1) receptors. Leukotrienes are inflammatory mediators released from cells like mast cells and eosinophils in response to various stimuli, including allergens. When leukotrienes bind to CysLT1 receptors located on various cells in the respiratory tract, including airway smooth muscle cells, eosinophils, and mast cells, they trigger a cascade of inflammatory responses. These responses include:

• Bronchoconstriction: Narrowing of the airways, leading to difficulty breathing.
• Airway Edema: Swelling of the airway lining.
• Mucus Secretion: Increased production of thick mucus.
• Inflammatory Cell Infiltration: Recruitment of inflammatory cells like eosinophils to the airways, perpetuating inflammation.

By competitively binding to the CysLT1 receptor, montelukast blocks the binding of cysteinyl leukotrienes (LTC4, LTD4, and LTE4) to this receptor. This blockade prevents the downstream inflammatory effects, thereby reducing bronchoconstriction, airway edema, mucus production, and eosinophilic inflammation. Unlike some other asthma medications, montelukast does not inhibit the synthesis of leukotrienes; rather, it targets their receptor.

Clinical Uses & Indications

The primary indications for montelukast, as approved by regulatory bodies like the U.S. Food and Drug Administration (FDA), include:

Asthma

Montelukast is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients (12 months of age and older). It is particularly effective in patients with mild to moderate persistent asthma. It can be used as an add-on therapy for patients whose asthma is inadequately controlled on inhaled corticosteroids or for those with asthma who are not candidates for inhaled corticosteroids. It helps to:

• Reduce the frequency and severity of asthma exacerbations.
• Improve daily asthma symptoms, including daytime and nighttime awakenings.
• Enhance lung function.
• Reduce the need for rescue medications (e.g., short-acting beta-agonists).

It is important to note that montelukast is not indicated for the relief of acute bronchospasm (i.e., for acute asthma attacks). Patients using montelukast should have a short-acting beta-agonist available for acute episodes.

Allergic Rhinitis

Montelukast is also indicated for the relief of symptoms of seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis in patients 12 months of age and older. It effectively manages symptoms such as:

• Sneezing
• Nasal congestion
• Rhinorrhea (runny nose)
• Nasal pruritus (itchy nose)
• Ocular symptoms (itchy, watery eyes)

By blocking the effects of leukotrienes, montelukast helps to reduce the inflammation and congestion associated with allergic reactions in the nasal passages.

Exercise-Induced Bronchoconstriction (EIB)

Montelukast is indicated for the prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. Patients are advised to take a single dose of montelukast approximately 2 hours before exercise. While it can prevent EIB, it should not be used for the acute treatment of exercise-induced bronchospasm that has already begun.

Dosage & Administration

Montelukast is available in several dosage forms to accommodate different age groups and preferences:

• Tablets: Typically available in 10 mg strengths for adults and adolescents.
• Chewable Tablets: Available in 4 mg and 5 mg strengths, suitable for younger children.
• Oral Granules: Available in a 4 mg packet, designed for infants and young children who have difficulty swallowing tablets.

The typical dosage and administration guidelines are as follows:

Indication	Age Group	Dosage Form	Dosage Frequency
Asthma and Allergic Rhinitis	Adults and Adolescents (15 years and older)	10 mg tablet	Once daily in the evening
Asthma and Allergic Rhinitis	Pediatric patients (6 to 14 years)	5 mg chewable tablet	Once daily in the evening
Asthma and Allergic Rhinitis	Pediatric patients (2 to 5 years)	4 mg chewable tablet or 4 mg oral granules	Once daily in the evening
Asthma and Allergic Rhinitis	Pediatric patients (12 to 23 months)	4 mg oral granules	Once daily in the evening
Exercise-Induced Bronchoconstriction	Adults and Adolescents (15 years and older)	10 mg tablet	Approximately 2 hours before exercise

Important Administration Notes:

• Montelukast should be taken daily, even when asymptomatic, to maintain its therapeutic effect.
• For oral granules, the contents can be mixed with a small amount of soft food (e.g., applesauce, mashed carrots, rice) or placed directly in the mouth. Do not store the mixture.
• Patients should be advised to continue taking montelukast as prescribed and not to discontinue it abruptly or reduce the dose without consulting their healthcare provider.
• Montelukast is not a substitute for inhaled or oral corticosteroids and should not be used to replace them unless directed by a physician.

Side Effects & Safety

Like all medications, montelukast can cause side effects, although not everyone experiences them. The side effects can range from common and mild to rare but serious.

Common Side Effects

These typically occur in a small percentage of patients and often resolve on their own:

• Headache
• Abdominal pain
• Diarrhea
• Nausea
• Rash
• Increased liver enzymes (transient)

Serious Side Effects and Precautions

While rare, montelukast has been associated with serious neuropsychiatric events. Patients and caregivers should be aware of these potential risks:

• Neuropsychiatric Events: There have been reports of mood changes, including depression, aggressive behavior, suicidal thoughts, and suicide. The FDA has issued warnings regarding these potential effects. Patients experiencing any unusual changes in mood, behavior, or sleep patterns should contact their healthcare provider immediately.
• Churg-Strauss Syndrome (Eosinophilic Vasculitis): In rare cases, patients with asthma who are treated with montelukast may develop a condition characterized by lung and nerve inflammation (vasculitis) with or without eosinophilia. Symptoms can include fever, flu-like symptoms, rash, and severe shortness of breath. This condition is a medical emergency.
• Allergic Reactions: Although montelukast treats allergic conditions, severe allergic reactions (anaphylaxis) are possible, though rare. Symptoms include hives, difficulty breathing, swelling of the face, lips, tongue, or throat.

Contraindications

Montelukast is generally well-tolerated, but it is contraindicated in patients with known hypersensitivity to montelukast or any other ingredient in the formulation.

Important Note: Patients should always discuss their medical history and any concerns with their healthcare provider before starting montelukast. The benefits of the medication should be weighed against the potential risks.

Drug Interactions

Montelukast has a relatively low potential for drug interactions, primarily due to its metabolic pathway. It is metabolized in the liver by cytochrome P450 enzymes, mainly CYP3A4, but also CYP2C8 and CYP2C9.

Notable potential interactions include:

• Drugs that induce or inhibit CYP3A4: Medications that strongly induce CYP3A4 (e.g., rifampin, phenobarbital, phenytoin) could potentially decrease montelukast levels, although clinical significance is often minimal. Conversely, strong inhibitors of CYP3A4 might increase montelukast levels, but this is generally not considered clinically significant due to montelukast's favorable safety profile and pharmacokinetic characteristics.
• Phenobarbital: Concomitant administration of montelukast with phenobarbital resulted in a significant increase in the AUC of montelukast. This interaction is generally not considered to necessitate a dose adjustment.
• Theophylline: Some studies suggest that montelukast may affect the metabolism of theophylline, but this interaction is typically not clinically significant.

It is crucial for patients to inform their healthcare provider about all medications they are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements, to ensure safe and effective use of montelukast.

Molecular Properties

Understanding the molecular properties of montelukast is key to appreciating its mechanism of action and potential for drug development. The molecule's structure dictates its interaction with biological targets and its pharmacokinetic behavior.

• Chemical Name: (R,E)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid
• Molecular Formula: C₃₅H₃₆ClN O₃S
• Molecular Weight: 585.69 g/mol
• Structure Description: Montelukast is a complex organic molecule characterized by several distinct functional groups and structural motifs. It features a quinoline ring system, which is a heterocyclic aromatic compound containing nitrogen. Attached to the quinoline is a vinyl group, which forms part of a larger conjugated system. The molecule also contains a thiomethyl ether linkage, a cyclopropane ring, and a carboxylic acid group. The presence of a chiral center contributes to its stereochemistry. The overall structure is designed to fit specifically into the binding pocket of the CysLT1 receptor.
• SMILES Notation: CC(C)(O)c1ccccc1CC/C(SCC1(CC(=O)O)CC1)=C\c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1

The SMILES (Simplified Molecular Input Line Entry System) notation provided, CC(C)(O)c1ccccc1CC/C(SCC1(CC(=O)O)CC1)=C\c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1, is a linear string of characters that uniquely represents the chemical structure of montelukast. This notation is invaluable in computational chemistry and drug discovery, allowing for the representation, searching, and analysis of molecular structures using computer algorithms.

Analyze Montelukast with MolForge

Montelukast exemplifies the intricate relationship between molecular structure and pharmacological activity. Its development involved extensive research into leukotriene pathways and receptor antagonism. For researchers and pharmaceutical scientists looking to explore molecules like montelukast, understand their properties, or discover novel drug candidates, advanced computational tools are indispensable.

MolForge's AI-powered platform offers cutting-edge solutions for molecular discovery and analysis. By leveraging sophisticated algorithms and vast datasets, MolForge enables you to:

• Predict molecular properties and potential biological activities.
• Design novel molecules with desired characteristics.
• Analyze complex drug structures and their interactions.
• Accelerate the drug discovery pipeline from ideation to preclinical development.

Explore the power of AI in drug discovery. Visit the MolForge dashboard to begin analyzing montelukast and discover the next generation of therapeutics.